JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

Inicio・Lista de Acciones・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Cerrado

1.66 -1.19

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.63

Máximo

1.72

Métricas clave
By Trading Economics
Ingresos	13M -43M
Margen de beneficios	-2,190.837
Empleados	171
EBITDA	17M -42M

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	+59.52% upside

Dividendos
By Dow Jones
Próximas Ganancias	6 nov 2025

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	6.8M 111M
Apertura anterior	2.85
Cierre anterior	1.66

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.43 / 1.6 Soporte y Resistencia

Pliant Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

3 nov 2025, 21:44 UTC

Ganancias

Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs

3 nov 2025, 23:44 UTC

Charlas de Mercado

Nikkei May Rise on Weaker Yen, Hopes for Govt Econ Steps -- Market Talk

3 nov 2025, 23:34 UTC

Charlas de Mercado

Gold Edges Lower Amid Lingering Worry Over China's Ending of Tax Incentive -- Market Talk

3 nov 2025, 23:28 UTC

Ganancias

Palantir Revenue Hits Another Record as Defense Work Booms -- 2nd Update

3 nov 2025, 23:24 UTC

Ganancias

Correct: Grab Holdings Sees FY2025 Adj Ebitda $490M-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3 nov 2025, 23:14 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Global Equities Roundup: Market Talk

3 nov 2025, 23:14 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Deterra's Next CEO Might Bring New Approach to Deals -- Market Talk

3 nov 2025, 23:12 UTC

Ganancias

Grab Holdings Sees FY2025 Adj Ebitda $490-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3 nov 2025, 23:09 UTC

Ganancias

Grab Holdings 3Q 2Q Adj EBITDA $136.0M Vs. $90.0M>GRAB

3 nov 2025, 23:09 UTC

Ganancias

Grab Holdings 3Q Net $17.0M Vs. Net $15.0M >GRAB

3 nov 2025, 23:09 UTC

Ganancias

Grab Holdings 3Q Rev $873.0M Vs. $716.0M >GRAB

3 nov 2025, 23:06 UTC

Charlas de Mercado

Ganancias

Palantir Execs Forecast Future of U.S. Workers In AI World -- Market Talk

3 nov 2025, 22:36 UTC

Charlas de Mercado

Ganancias

Palantir's U.S. Commercial Business Booms as It Expands AI -- Market Talk

3 nov 2025, 22:31 UTC

Ganancias

Franco-Nevada 3Q EPS $1.49 >FNV

3 nov 2025, 22:31 UTC

Ganancias

Franco-Nevada 3Q Rev $487.7M >FNV

3 nov 2025, 22:24 UTC

Charlas de Mercado

Xero Bulls Expect Improving U.S. Momentum in 1H -- Market Talk

3 nov 2025, 22:19 UTC

Adquisiciones, fusiones, absorciones

Starbucks Agrees to Sell Stake in China Business -- WSJ

3 nov 2025, 21:59 UTC

Charlas de Mercado

RBA Set To Keep Rates On Hold; Remain Data Dependent -- Market Talk

3 nov 2025, 21:54 UTC

Charlas de Mercado

Ganancias

Westpac's Tech Challenge Keeps Jefferies Cautious -- Market Talk

3 nov 2025, 21:54 UTC

Charlas de Mercado

Ganancias

Global Equities Roundup: Market Talk

3 nov 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

3 nov 2025, 21:49 UTC

Ganancias

Palantir Revenue Hits Another Record as Defense Work Booms -- Update

3 nov 2025, 21:40 UTC

Ganancias

Barry Diller's IAC Inks AI Deal With Microsoft. That Isn't Why the Stock Is Sliding. -- Barrons.com

3 nov 2025, 21:31 UTC

Charlas de Mercado

Mexican Manufacturing Indexes Pick Up in October -- Market Talk

3 nov 2025, 21:19 UTC

Ganancias

Palantir Revenue Hits Another Record as Defense Work Booms -- WSJ

3 nov 2025, 21:11 UTC

Adquisiciones, fusiones, absorciones

Pfizer Reports Earnings Tuesday. Management Has Big Questions to Answer. -- Barrons.com

3 nov 2025, 21:11 UTC

Ganancias

Diamondback Energy: Increasing Full Yr Oil Production Guidance to 495-498 MBO/d and Increasing Annual BOE Guidance to 910-920 MBOE/d >FANG

3 nov 2025, 21:07 UTC

Ganancias

Palantir Technologies: Raising 2025 U.S. Comml Rev Guidance to in Excess of $1.433B, Representing a Growth Rate of at Least 104% >PLTR

3 nov 2025, 21:05 UTC

Ganancias

Vertex Pharmaceutic Sees 2025 Rev $11.9B-$12B >VRTX

3 nov 2025, 21:05 UTC

Ganancias

Palantir Technologies 3Q Net $475.6M >PLTR

Comparación entre iguales

Cambio de precio

Pliant Therapeutics Inc previsión

Precio Objetivo

By TipRanks

59.52% repunte

Estimación a 12 Meses

Media 2.68 USD 59.52%

Máximo 4 USD

Mínimo 1.7 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.43 / 1.6Soporte y Resistencia

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.